Target Price | $14.86 |
Price | $7.89 |
Potential |
88.31%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target Travere Therapeutics Inc 2025 .
The average Travere Therapeutics Inc target price is $14.86.
This is
88.31%
register free of charge
$20.00
153.49%
register free of charge
$9.00
14.07%
register free of charge
|
|
A rating was issued by 16 analysts: 11 Analysts recommend Travere Therapeutics Inc to buy, 5 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Travere Therapeutics Inc stock has an average upside potential 2025 of
88.31%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 145.24 | 215.00 |
31.50% | 48.03% | |
EBITDA Margin | -232.86% | -106.01% |
125.98% | 54.48% | |
Net Margin | -237.91% | -120.09% |
51.66% | 49.52% |
13 Analysts have issued a sales forecast Travere Therapeutics Inc 2024 . The average Travere Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Travere Therapeutics Inc EBITDA forecast 2024. The average Travere Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Travere Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Travere Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.54 | -3.39 |
3.89% | 25.33% | |
P/E | negative | |
EV/Sales | 2.62 |
15 Analysts have issued a Travere Therapeutics Inc forecast for earnings per share. The average Travere Therapeutics Inc <a href=/blog/eps>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Travere Therapeutics Inc stock is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth metrics and future valuations:
Travere Therapeutics Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.